SuperworthBiogen EPS BIIB
Diluted earnings per share by quarter and over the last twelve months, from 2008.
- Last 12 months, to Jun 30, 2026
- $5.65
- Latest quarter, Q2 FY26
- $0.66
- −85% on a year earlier
- Fiscal year 2025
- $8.81
- −21% on the year before
Biogen's earnings per share was $5.65 over the twelve months to Jun 30, 2026, down 46% on a year earlier.
In its latest quarter, Q2 FY26, it was $0.66, down 85% on the same quarter a year before.
Over the five fiscal years to FY2025 it shrank 18% a year on average.
Earnings per share over time
Fiscal year by fiscal year
| Fiscal year | EPS | Change |
|---|---|---|
| FY2025 | $8.81 | −21% |
| FY2024 | $11.19 | +40% |
| FY2023 | $7.98 | −62% |
| FY2022 | $20.93 | +101% |
| FY2021 | $10.40 | −57% |
| FY2020 | $24.45 | −22% |
| FY2019 | $31.47 | +46% |
| FY2018 | $21.60 | +81% |
| FY2017 | $11.92 | −30% |
| FY2016 | $16.92 | +10% |
| FY2015 | $15.34 | +24% |
| FY2014 | $12.39 | +58% |
| FY2013 | $7.82 | +36% |
| FY2012 | $5.76 | +15% |
| FY2011 | $5.03 | +27% |
Each fiscal year is the twelve months to its fourth quarter.
Quarter by quarter
| Quarter | Ended | EPS | On a year earlier | Last 12 months |
|---|---|---|---|---|
| Q2 FY26 | $0.66 | −85% | $5.65 | |
| Q1 FY26 | $2.15 | +31% | $9.32 | |
| Q4 FY25 | −$0.33 | −118% | $8.81 | |
| Q3 FY25 | $3.17 | +19% | $10.97 | |
| Q2 FY25 | $4.33 | +8% | $10.46 | |
| Q1 FY25 | $1.64 | −39% | $10.13 | |
| Q4 FY24 | $1.83 | +7% | $11.19 | |
| Q3 FY24 | $2.66 | n/a | $11.07 | |
| Q2 FY24 | $4.00 | −2% | $7.94 | |
| Q1 FY24 | $2.70 | +1% | $8.01 | |
| Q4 FY23 | $1.71 | −55% | $7.98 | |
| Q3 FY23 | −$0.47 | −106% | $10.06 |
Against its peers
Companies in Drug Manufacturers - General nearest Biogen's size, closest first, today.
| Company | EPS, 12 months | Growth |
|---|---|---|
| BIIBBiogen | $5.65 | −46% a year |
| JAZZJazz Pharmaceuticals | $14.62 | |
| BMYBristol-Myers Squibb | $4.54 | +83% a year |
| BMRNBiomarin Pharmaceutical | $0.37 | −89% a year |
| CORTCorcept Therapeutics | $0.42 | −63% a year |
| PTGXProtagonist Therapeutics | $1.03 | +47% a year |
| TGTXTG Therapeutics | $2.74 | +641% a year |
| PFEPfizer | $0.76 | −60% a year |
| ALKSAlkermes plc. | $0.38 | −82% a year |
| GILDGilead Sciences | −$2.67 | −153% a year |
| AMRXAmneal Pharmaceuticals | $0.49 | +4800% a year |
| Peer median | $0.63 |
Where Biogen ranks
What the EPS figure tells you
Net income divided by diluted shares. The denominator of PE.
One-off charges and gains swing it. The TTM view smooths a single odd quarter.
More on Biogen
Valuation data, not investment advice. Prices as of . Reported figures come from the company's filings with the SEC.